

L3	E ETHANOL/CN
	1 S E15
	E DIAZEPAM/CN
L4	1 S E27
	E HYDROCORTISONE/CN
L5	1 S E39
	E CYCLOPHOSPHAMIDE/CN
L6	1 S E51
	E PHENAZEPAM/CN
L7	1 S E63

FILE 'CAPLUS' ENTERED AT 17:04:18 ON 29 JUL 2010

L8	355944 S L3-L7
L9	3876 S L8 AND (?HOMEOPATH? OR POTENTIAT? OR POTENTISAT?)
L10	3313 S L9 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)
L11	1979 S L3 AND (?HOMEOPATH? OR POTENTIAT? OR POTENTISAT?)
L12	69 S L3 AND (?HOMEOPATH?)
L13	43 S L12 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)

L13 ANSWER 17 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN
 AB The title method comprises (1) diluting any liqs. (excluding alcs.) in an alc. solution, (2) shaking the resulting soiins., (3) repeating the steps of diluting and shaking multiple times, and (4) impregnating the product into a solid saccharide.

ACCESSION NUMBER: 2001:573236 CAPLUS Full-text
 DOCUMENT NUMBER: 135:142267
 TITLE: Simple method for the manufacture of homeopathic drug delivery systems
 INVENTOR(S): Yui, Tomoko
 PATENT ASSIGNEE(S): Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 2001213790 20000201 <-- PRIORITY APPLN. INFO.: 20000201 <-- IPC1 A61K0035-20 [ICM,7]; A61K0033-00 [ICS,7]; A61P0017-00 [ICS,7]; A61P0043-00 [ICS,7] IPC2 A61K0033-00 [I,C*]; A61K0033-00 [I,A]; A61K0035-20 [I,C*]; A61K0035-20 [I,A]; A61P0017-00 [I,C*]; A61P0017-00 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]	A	20010807	JP 2000-23936	
CC 63-6 (Pharmaceuticals) ST alc diln shaking homeopathic drug delivery IT Agitation (mechanical) Dilution (alc. dilution and shaking for preparation of homeopathic drug delivery systems for bioactive liqs.)				

IT Alcohols, biological studies
Polysaccharides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alc. dilution and shaking for preparation of homeopathic drug
delivery systems for bioactive liqs.)

IT Drug delivery systems
(homeopathic; alc. dilution and shaking for preparation of
homeopathic drug delivery systems for bioactive liqs.)

IT 64-17-5, Ethanol, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alc. dilution and shaking for preparation of homeopathic drug
delivery systems for bioactive liqs.)

L13 ANSWER 28 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN

AB Carrier solvents in pharmaceuticals should be excipient. Ethanol in liquid preps. intended for children is an industry decision but it is a metabolically active substrate, sometimes found in subtherapeutic or subtoxic doses. Worst offenders in this respect are prescription drugs for long-term treatment which inevitably subject patients to chronic passive exposure. One hundred three such preps. were identified from the Italian pharmacopoeia with more than 20 mg/dL ethanol. OTCs and homeopathic remedies were also found to contain large amts. (up to 60% volume) of ethanol with even less clin. need or benefit. Domestic sources other than medicinals were found to account for negligible amts. (<2 mg/dL). Hepatic and extrahepatic enzyme route switching, hepatic blood flow and plasma clearance are all age-dependent and the growth process itself is increasingly thought to impact on drug pharmacokinetics. The implications for pediatric prescribers are that trademarks for the same active ingredient should be differentially assessed against expected length of treatment and ethanol amts., preferring non-alc. alternatives whenever possible. Yet the medical literature has paradoxically ignored the need for a toxicol. re-assessment of ethanol in children medications and acceptable risk thresholds have not been determined

ACCESSION NUMBER: 1999:204080 CAPLUS Full-text
DOCUMENT NUMBER: 130:333988
TITLE: Ethanol in medicines and other products
intended for children: commentary on a medical paradox
AUTHOR(S): Fiocchi, A.; Riva, E.; Giovannini, M.
CORPORATE SOURCE: Department of Paediatrics of the University of
Milan
Institute, Medical School at the San Paolo Biomedical
Milan, 20142, Italy
SOURCE: Nutrition Research (New York) (1999), 19(3),
373-379
CODEN: NTRSDC; ISSN: 0271-5317
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
CC 4-7 (Toxicology)
IT 64-17-5, Ethanol, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ethanol in medicines and other products intended for
children-commentary on medical paradox)

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE
FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L13 ANSWER 29 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN
AB A method of therapy for drug addiction is claimed. Potentiated morphine, prepared by repeated and successive dilution and agitation of morphine solution or a mixture of opium alkaloids containing 50-95 weight% morphine, morphine hydrochloride, and apomorphine or other morphine derivs. are used practically as homeopathic preps. The combined administration of potentiated morphine and an addnl. potentiated homeopathic remedy, derived from the original habitual narcotic substance for which a patient has a pathol. craving, is suggested for periods of critical intoxication and abstinence.

ACCESSION NUMBER: 1998:572337 CAPLUS Full-text
DOCUMENT NUMBER: 129:170539
ORIGINAL REFERENCE NO.: 129:34512h,34513a
TITLE: Method for the treatment of drug addiction and homeopathic remedy
INVENTOR(S): Epshtain, Oleg Iiich
PATENT ASSIGNEE(S): Russia
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9835680	A1	19980820	WO 1998-RU23	
19980209 <--				
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, LC, LK, RO, RU,	EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, CI, CM,			
RU 2104006	C1	19980210	RU 1997-101895	
19970214 <--				
AU 9861264	A	19980908	AU 1998-61264	
19980209 <--				
PRIORITY APPLN. INFO.: 19970214 <--			RU 1997-101895	A
19980209 <--			WO 1998-RU23	W
IPCI A61K0314-85 [ICM]				
IPCR A61K0031-485 [I,C*]; A61K0031-485 [I,A]; A61P0025-00 [I,C*];				

A61P0025-30
[I,A]
CC 1-11 (Pharmacology)
Section cross-reference(s): 4, 63
ST therapy drug addiction homeopathic opium alkaloid
IT Drug delivery systems
(homeopathic; method for treatment of drug addiction by homeopathic preps. of opium alkaloids)
IT Alcoholism
Drug dependence
Drug withdrawal
(method for treatment of drug addiction by homeopathic preps. of opium alkaloids)
IT Opioids
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(method for treatment of drug addiction by homeopathic preps. of opium alkaloids)
IT 50-36-2, Cocaine 50-37-3, LSD 52-26-6, Morphine hydrochloride 57-27-2, Morphine, biological studies 58-00-4, Apomorphine 64-17-5, Ethanol, biological studies
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(method for treatment of drug addiction by homeopathic preps. of opium alkaloids)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 30 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN
AB The present invention relates mainly to a drug regimen involving ethanol amplified by diluting and shaking it many times according to a homeopathic method consisting in taking as a starting material Et alc. and diluting it in the ratio of 100/10000. The preferred embodiment consists in combining amplified ethanol and morphine, obtained by diluting and shaking them many times according to said homeopathic method, either from an opium alkaloid or morphine or a mixture of opium alkaloids with a mass of 65 to 95 % of morphine or from hydrochloride morphine diluted in the ratio of 200/1000.
ACCESSION NUMBER: 1998:542961 CAPLUS Full-text
DOCUMENT NUMBER: 129:166229
ORIGINAL REFERENCE NO.: 129:33705a, 33708a
TITLE: Alcoholism treatment and homeopathic pharmaceutical product
INVENTOR(S): Epshtein, Oleg Iliich
PATENT ASSIGNEE(S): Russia
SOURCE: PCT Int. Appl., 9 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9833493	A1	19980806	WO 1998-RU17	
19980128 <--				
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
RU 2103999	C1	19980210	RU 1997-101100	
19970131 <--				
AU 9861263	A	19980825	AU 1998-61263	
19980128 <--				
PRIORITY APPLN. INFO.:			RU 1997-101100	A
19970131 <--			WO 1998-RU17	W
19980128 <--				
IPCI A61K0031-045 [ICM,6]; A61K0031-485 [ICS,6]				
IPCR A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-485 [I,C*]; A61K0031-485 [I,A]; A61P0025-00 [I,C*]; A61P0025-32 [I,A]				
CC 63-6 (Pharmaceuticals)				
Section cross-reference(s): 4				
ST homeopathy alcoholism treatment formulation				
IT Alcoholism				
(alcoholism treatment and homeopathic pharmaceutical product)				
IT Drug delivery systems				
(homeopathic; alcoholism treatment and homeopathic pharmaceutical product)				
IT 52-26-6, Morphine hydrochloride 64-17-5, Ethanol, biological studies				
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (alcoholism treatment and homeopathic pharmaceutical product)				
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS				
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L13 ANSWER 31 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN
 AB Title only translated.

ACCESSION NUMBER: 1998:323561 CAPLUS Full-text

DOCUMENT NUMBER: 128:299575

ORIGINAL REFERENCE NO.: 128:59271a,59274a

TITLE: Homeopathic agent for recovery of psychophysiological homeostasis damaged by alcohol

INVENTOR(S): intake
Vorobeva, Tamara Mikhajlovna; Epshtejn, Oleg
I.; Ilchikov, Mikhail Z.
PATENT ASSIGNEE(S): Vorobeva, Tamara Mikhajlovna, Ukraine;
Epshtejn, Oleg Illich; Ilchikov, Mikhail Zakharovich
SOURCE: Russ. From: Izobreteniya 1997, (35), 370.
CODEN: RUXXE7
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
RU 2099052 19961226 <--	C1	19971220	RU 1996-123975	
PRIORITY APPLN. INFO.: 19961226 <--			RU 1996-123975	
IPC1 A61K0031-045 [ICM,6]; A61K0009-08 [ICS,6]				
IPC2 A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0009-08 [I,C*];				
A61K0009-08 [I,A]; A61P0025-00 [I,C*]; A61P0025-32 [I,A]				
CC 63-6 (Pharmaceuticals)				
Section cross-reference(s): 4				
ST homeopathic formulation alcoholism psychophysiolog				
IT Alcoholism (Homeopathic agent for recovery of psychophysiolog. homeostasis damaged by alc. intake)				
IT Drug delivery systems (homeopathic; Homeopathic agent for recovery of psychophysiolog. homeostasis damaged by alc. intake)				
IT 64-17-5, Ethanol, biological studies RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (Homeopathic agent for recovery of psychophysiolog. homeostasis damaged by alc. intake)				
OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)				

L13 ANSWER 32 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN
AB The present invention relates to an agent for acting upon the organism and to biol. active substances. This invention more precisely relates to a potential preparation which is obtained by repeatedly cultivating and shaking a specific starting product having toxic properties and being poisonous to the organism (narcotics, alc., nicotine, industrial poisons, military poisonous substances). In order to cure alcoholism, this method uses ethanol as a starting substance during the potentialization, while it uses an opium alkaloid, morphine or morphine hydrochloride for curing drug problems. The potential agent of the present invention may be used in any medical homeopathic form and preferably together with the starting product.

ACCESSION NUMBER: 1998:219690 CAPLUS Full-text
DOCUMENT NUMBER: 128:279704
ORIGINAL REFERENCE NO.: 128:55292h, 55293a
TITLE: Agent for acting upon the organism
INVENTOR(S): Epshtein, Oleg Iliich
PATENT ASSIGNEE(S): Epshtein, Oleg Iliich, Russia
SOURCE: PCT Int. Appl., 10 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9814162	A1	19980409	WO 1997-RU305	
19970929 <--				
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
FI, FR, RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
RU 2132181	C1	19990627	RU 1996-118931	
19960930 <--				
AU 9747293	A	19980424	AU 1997-47293	
19970929 <--				
PRIORITY APPLN. INFO.:			RU 1996-118931	A
19960930 <--			WO 1997-RU305	W
19970929 <--				
IPCI A61J0003-00 [ICM,6]; A61K0031-045 [ICS,6]; A61K0031-485 [ICS,6]; A61K0035-78 [ICS,6]				
IPCR A61J0003-00 [I,C*]; A61J0003-00 [I,A]; A61K0031-045 [I,C*]; A61K0031-045 [I,A]; A61K0031-047 [I,A]; A61K0031-472 [I,C*]; A61K0031-472 [I,A]; A61K0031-485 [I,C*]; A61K0031-485 [I,A]; A61K0036-00 [I,C*]; A61K0036-00 [I,A]; A61P0025-00 [I,C*]; A61P0025-30 [I,A]; A61P0025-32 [N,A]; A61P0025-34 [N,A]; A61P0025-36 [N,A]				
CC 4-7 (Toxicology)				
Section cross-reference(s): 1				
IT 52-26-6, Morphine hydrochloride	57-27-2, Morphine, biological studies			
64-17-5, Ethanol, biological studies				
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL				
(Biological study); USES (Uses)				

(chemical and drug toxicity and the potential treatment)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE
FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L13 ANSWER 33 OF 43 CAPLUS COPYRIGHT 2010 ACS on STN
AB Title only translated.
ACCESSION NUMBER: 1998:42854 CAPLUS Full-text
DOCUMENT NUMBER: 128:58520
ORIGINAL REFERENCE NO.: 128:11367a,11370a
TITLE: Homeopathic agent for alcohol dependence
treatment
INVENTOR(S): Sergeev, Aleksej V.
PATENT ASSIGNEE(S): Russia
SOURCE: Russ. From: Izobreteniya 1997, (24), 232.
CODEN: RUXXE7
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	----
RU 2088221	C1	19970827	RU 1996-100687	
19960110 <--				
PRIORITY APPLN. INFO.:			RU 1996-100687	
19960110 <--				
IPC1 A61K0031-00 [ICM,6]; A61K0035-78 [ICS,6]				
IPCR A61K0036-71 [I,A]; A61K0031-00 [I,C*]; A61K0031-00 [I,A];				
A61K0036-185				
[I,C*]; A61K0036-49 [I,A]; A61K0036-56 [I,A]; A61P0025-00 [I,C*];				
A61P0025-32 [I,A]				
CC 4-7 (Toxicology)				
Section cross-reference(s): 63				
ST alc dependence homeopathic				
IT Alcoholism				
Drug dependence				
Oak (Quercus)				
Ranunculus bulbosus				
Strychnos nux-vomica				
(homeopathic agent for alc. dependence treatment)				
IT 64-17-5, Ethanol, biological studies				
RL: ADV (Adverse effect, including toxicity); BIOL (Biological				
study)				
(homeopathic agent for alc. dependence treatment)				

L14 6 S L4 AND (?HOMEOPATH?)
L15 4 S L14 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)

L15 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
AB Said invention is characterized by the application of a small and
mini doses of an activated medical substance in the form of an
agent for potentiating curing effects, i.e. enhancing action of
the therapeutic dose of the same medical substance.

ACCESSION NUMBER: 2005:395147 CAPLUS Full-text
 DOCUMENT NUMBER: 142:417235
 TITLE: Agent for potentiating the therapeutic effects
 of medicinal agents
 of
 INVENTOR(S): Epshtain, Oleg Iliich
 PATENT ASSIGNEE(S): Russia
 SOURCE: PCT Int. Appl., 20 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039636 20040927 <--	A1	20050506	WO 2004-RU374	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
RU 2253478 20031001 <--	C1	20050610	RU 2003-129126	
US 20070123518 20060331 <--	A1	20070531	US 2006-574524	
PRIORITY APPLN. INFO.: 20031001 <--			RU 2003-129126	A
20040927			WO 2004-RU374	W
IPCI A61K0045-00 [ICM,7]; A61J0003-00 [ICS,7] IPCR A61K0045-00 [I,A]; A61K0031-47 [I,C*]; A61K0031-47 [I,A]; A61K0031-485 [I,C*]; A61K0031-485 [I,A]; A61K0031-551 [I,C*]; A61K0031-5513 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]				
CC 63-6 (Pharmaceuticals)				
ST drug potentiation method anxiolytic homeopathy				
IT Drug delivery systems				

(homeopathic; agent for potentiating the therapeutic effects of medicinal agents)

IT 50-18-0, Cyclophosphane 50-23-7, Hydrocortisone 57-27-2,
 Morphine,
 biological studies 439-14-5, Diazepam 12794-10-4,
 Benzodiazepine 51753-57-2, Phenazepam
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (agent for potentiating the therapeutic effects of medicinal agents)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE
 FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE
 RE FORMAT

L15 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN

AB Method is disclosed for the treatment of chronic relapsing lip fissures and combinations of chronic relapsing lip fissures with exfoliative or atopic chelitis. Method involves administration of proteolytic enzyme, application of an ointment of the complex composition on fissure and entire red border of the lips, administration of lidocaine blockade with premedication with apodiazepam at the dose of 5 mg by sublingual route, using ointment "Lorinden C", application of He-Ne laser treatment on damaged lip sites, administration of anti-histaminic prepns., antiallergic diet and correction of psycho-emotional state. Treatment is carried out on the background of every day application of oral gels for lips protection and polyvitamins intake. Homeopathic ointment "Traumel" is prescribed for children instead of ointment "Lorinden C". Method ensures high effectiveness of treatment with the following absence of the relapses of the disease; neuro-dystrophic, inflammatory processes around lips and perioral skin are eliminated.

ACCESSION NUMBER: 2004:459069 CAPLUS Full-text
 DOCUMENT NUMBER: 141:65131
 TITLE: Method for the treatment of chronic relapsing
 lip
 fissures and combinations of chronic relapsing
 lip
 fissures with exfoliative or atopic chelitis
 INVENTOR(S): Brusenina, N. D.; Rybalkina, E. A.
 PATENT ASSIGNEE(S): Moskovskii Gosudarstvennyi Mediko-
 Stomatologicheskii
 SOURCE: Universitet, Russia
 Russ., No pp. given
 CODEN: RUXXE7
 DOCUMENT TYPE: Patent
 LANGUAGE: Russian
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2227017 20021224 <--	C2	20040420	RU 2002-134786	
PRIORITY APPLN. INFO.:			RU 2002-134786	

20021224 <--
 IPCI A61K0009-06 [ICM, 7]; A61N0005-06 [ICS, 7]; A61P0001-04 [ICS, 7];
 A61P0001-00
 [ICS, 7,C*]
 IPCR A61K0009-06 [I,C*]; A61K0009-06 [I,A]; A61N0005-06 [I,C*];
 A61N0005-06
 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A]
 CC 1-12 (Pharmacology)
 Section cross-reference(s): 2, 7, 8, 18, 63
 ST lidocaine proteolytic enzyme sublingual apodiazepam Lorinden C lip fissure; antidepressant antihistaminic antiallergic diet homeopathic ointment Traumel laser
 IT Drug delivery systems
 (homeopathic, Traumel ointment; method for treatment of chronic relapsing lip fissures and combinations of chronic relapsing
 lip fissures with exfoliative or atopic chelitis)
 IT Therapy
 (homeopathy; method for treatment of chronic relapsing lip fissures and combinations of chronic relapsing lip fissures
 with
 exfoliative or atopic chelitis)
 IT 137-58-6, Lidocaine 439-14-5, Apo-diazepam 9001-92-7,
 Proteolytic enzyme
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (method for treatment of chronic relapsing lip fissures and
 combinations of chronic relapsing lip fissures with exfoliative
 or
 atopic chelitis)

L15 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN

AB The inventive curative method for a pathol. syndrome consists in inserting into an organism activated forms of minute antibody doses which are produced by means of a repeated successive dilution and an external action carried out on an antigen, e.g. a substance or medicinal preparation influencing a mechanism forming said pathol. syndrome. The inventive medicinal preparation for curing the pathol. syndrome comprises an activated form of minute doses of monoclonal, polyclonal or natural antibodies. Said antibodies are produced by means of a repeated successive dilution and an external action, preferably using homeopathic technol., which is carried out on an antigen, e.g. a substance or medicinal preparation directly promoting the formation of the pathol. syndrome or participating in regulating mechanisms for the formation thereof. Activated forms of minute doses of antibodies to the antigens of an exogenous and endogenous nature, autoantigens and fetal antigens, are used. Anti-idiotypic antibodies are also used.

ACCESSION NUMBER: 2001:935434 CAPLUS Full-text
DOCUMENT NUMBER: 136:58848
TITLE: Curative method for pathologic syndromes and homeopathic medicinal preparations
INVENTOR(S): Epshtein, Oleg Iliich; Kolyadko, Tamara
Mikhailovna;
PATENT ASSIGNEE(S): Shtark, Mark Borisovich
Russia

SOURCE: PCT Int. Appl., 100 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Russian

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001097842	A1	20011227	WO 2001-RU239	
20010619 <--				
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
RU 2181297	C2	20020420	RU 2000-115594	
20000620 <--				
CA 2413358	A1	20011227	CA 2001-2413358	
20010619 <--				
AU 2001069646	A	20020102	AU 2001-69646	
20010619 <--				
EP 1295606	A1	20030326	EP 2001-948169	
20010619 <--				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20030099636	A1	20030529	US 2002-311666	
20021217 <--				
US 20070224187	A1	20070927	US 2007-656226	
20070122 <--				
US 20080019982	A1	20080124	US 2007-656322	
20070122 <--				
US 20080050392	A1	20080228	US 2007-656217	
20070122 <--				
US 20080050360	A1	20080228	US 2007-656218	
20070122 <--				
US 20080131440	A1	20080605	US 2007-656216	
20070122 <--				
US 20100166762	A1	20100701	US 2010-701197	
20100205 <--				
PRIORITY APPLN. INFO.:			RU 2000-115594	A
20000620 <--				
20010619 <--			WO 2001-RU239	W
20021217 <--			US 2002-311666	A3

20070122

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

IPCI A61K0039-395 [ICM,7]; A61P0037-00 [ICS,7]

IPCR A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61P0037-00 [I,C*];

A61P0037-00

[I,A]; C07K0016-00 [I,C*]; C07K0016-00 [I,A]; C07K0016-18 [I,C*];

C07K0016-24 [I,A]; C07K0016-26 [I,A]; C07K0016-44 [I,C*];

C07K0016-44

[I,A]

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 15

ST antibody homeopathic formulation

IT Blood-group substances

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(Rh, antibodies to; curative method for pathol. syndromes and homeopathic medicinal preps.)

IT Cannabinoids

Interferons

Prostaglandins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(antibodies to; curative method for pathol. syndromes and homeopathic medicinal preps.)

IT Antibodies and Immunoglobulins

Antigens

Haptens

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC

(Process);

USES (Uses)

(curative method for pathol. syndromes and homeopathic medicinal preps.)

IT Drug delivery systems

(homeopathic; curative method for pathol. syndromes and homeopathic medicinal preps.)

IT Antibodies and Immunoglobulins

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC

(Process);

USES (Uses)

(monoclonal; curative method for pathol. syndromes and homeopathic medicinal preps.)

IT 50-02-2 50-06-6, Phenobarbital, biological studies 50-23-7, Hydrocortisone 50-28-2, Estradiol, biological studies 50-35-1, Thalidomide 50-37-3, Lsd 50-48-6, Amitriptyline 50-49-7,

Imipramine

50-55-5, Reserpine 50-67-9, Serotonin, biological studies 50-78-2,

Aspirin 51-41-2, Noradrenalin 51-45-6, Histamine, biological studies

51-55-8, Atropine, biological studies 51-60-5, Proserine 51-61-6,

Dopamine, biological studies 51-84-3, Acetylcholine, biological studies

52-53-9, Verapamil 52-86-8, Haloperidol 53-86-1, Indomethacin 54-11-5, Nicotine 54-31-9, Furosemide 54-85-3, Isoniazid 55-

63-0,

Nitroglycerin 56-40-6, Glycine, biological studies 56-84-8,
Aspartic acid, biological studies 56-86-0, Glutamic acid, biological studies 57-27-2, Morphine, biological studies 57-41-0, Phenytoin 57-47-6, Physostigmine 57-66-9, Probenecid 57-92-1, Streptomycin, biological studies 58-08-2, Caffeine, biological studies 58-22-0, Testosterone 58-55-9, Theophylline, biological studies 58-82-2, Bradykinin 58-93-5, Hypothiazide 59-05-2, Methotrexate 59-26-7, Cordiamine 59-43-8, Thiamin, biological studies 59-66-5, Acetazolamide 59-67-6, Nicotinic acid, biological studies 59-92-7, Levodopa, biological studies 60-99-1, Tisercin 64-39-1, Promedol 71-63-6, Digitoxin 71-73-8, Thiopental sodium 76-57-3, Codeine 77-10-1, Phencyclidine 86-54-4, Apressin 87-33-2, Nitrosorbide 92-84-2, Phenothiazine 97-77-8, Disulfiram 103-90-2, Paracetamol 137-58-6, Lidocaine 146-22-5, Nitrazepam 298-46-4, Tegretol 299-42-3, Ephedrine 318-98-9, Anapriline 364-62-5, Metoclopramide 437-38-7, Fentanyl 439-14-5, Diazepam 443-48-1, Metronidazole 465-65-6, Naloxone 511-12-6, Dihydroergotamine 586-06-1, Orciprenaline 621-72-7, Dipazol 835-31-4, Naphthizine 982-43-4, Libexin 985-12-6, No-spa 1069-66-5, Depakin 1078-21-3, Phenibut 1134-47-0, Baclofen 1406-16-2, Vitamin d 1406-18-4, Vitamin e 1490-04-6, Menthol 1972-08-3, Tetrahydrocannabinol 2898-12-6, Mezepam 3644-61-9, Midocalm 3737-09-5, Ritmilen 3930-20-9, Sotalol 4205-91-8, Clofelin 5786-21-0, Azaleptine 6740-88-1, Ketamine 6893-02-3, Triiodothyronine 7085-55-4, Troxerutin 7491-74-9, Nootropil 9002-72-6, Somatotropin 9004-10-8, Insulin, biological studies 9005-49-6, Heparin, biological studies 9007-12-9, Calcitonin 9007-92-5, Glucagon, biological studies 9015-82-1, Angiotensin-converting enzyme 9015-94-5, Renin, biological studies 9025-82-5, Phosphodiesterase 9035-34-1, Cytochrome a 10540-29-1, Tamoxifen 11103-57-4, Vitamin A 11128-99-7, Angiotensin ii 12656-61-0, Cerebrolysin 13292-46-1, Rifampicin 13311-84-7, Flutamide 13392-18-2, Fenoterol 14286-84-1, Halidor 14402-89-2, Sodium nitroprusside 14611-51-9, Selegiline 14769-73-4, Levamisole 14838-15-4, Norephedrine 14976-57-9, Tavegil 15307-86-5, Diclofenac 15663-27-1, Cisplatin 15687-27-1, Ibuprofen 15876-67-2,

Ubretid 16110-51-3, Cromolyn 16773-42-5, Ornidazole 17479-19-5,
 Dihydroergocristine 18559-94-9, Salbutamol 19216-56-9,
 Prazosin 19774-82-4, Cordarone 20830-75-5, Digoxin 22254-24-6, Atrovent
 23214-92-8, Doxorubicin 23288-49-5, Probucol 23476-83-7,
 Prospidine 25614-03-3, Bromocryptine 25717-80-0, Molsidomine 27236-88-0,
 Sodium hydroxybutyrate 28797-61-7, Pirenzepine 29122-68-7, Atenolol
 31637-97-5, Etofibrate 34262-84-5 34580-13-7, Ketotifen
 34580-14-8,
 Zaditen 36282-47-0, Tramal 36894-69-6 39391-18-9,
 Cyclooxygenase 42399-41-7, Diltiazem 42408-82-2, Butorphanol 51753-57-2,
 Phenazepam 54063-53-5, Propafenone 54739-18-3, Fluvoxamine 54910-89-3,
 Fluoxetine 55142-85-3, Ticlopidine 57808-66-9, Motilium 59122-46-2,
 Misoprostol 59467-70-8, Midazolam 62571-86-2, Captopril 62683-29-8, Colony
 stimulating factor 66357-35-5, Ranitidine 66829-00-3,
 Aminalone 71320-77-9, Moclobemide 72841-18-0, Cytochrome a3 73590-58-6,
 Omeprazole 75438-57-2, Moxonidine 75847-73-3, Enalapril
 76824-35-6,
 Famotidine 79617-96-2, Sertraline 79794-75-5, Loratadine
 80214-83-1,
 Rulid 81093-37-0, Pravastatin 82626-48-0, Zolpidem 84057-84-
 1,
 Lamotrigin 85721-33-1, Ciprofloxacin 88040-23-7, Tseefepim
 96829-58-2, Orlistat 103628-46-2, Sumatriptan 106266-06-2,
 Risperidone 106463-17-6, Omnic 110942-02-4, Aldesleukin 111470-99-6,
 Norvasc 121181-53-1, Filgrastim 124750-99-8, Cozaar 142805-56-9,
 Topoisomerase ii 214692-62-3, Omez 383123-63-5, Detralex
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antibodies to; curative method for pathol. syndromes and
 homeopathic medicinal preps.)
 OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE
 THIS RECORD (6 CITINGS)
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE
 FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
 RE FORMAT

L15 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2010 ACS on STN
 AB An analgesic, antipyretic, anti-inflammatory, anti-influenzal
 preparation is disclosed which comprises (parts by weight) aspirin
 10-500, paracetamol or ascorbic acid 10-500, caffeine 1-50,
 diazepam 1-50 or amitryptiline 1-20 or thioridazine 1-20, or
 hydroxyzine 1-20 or promethazine 1-30, or a mixture of 1-50 parts
 phenylpropanolamine and 1-50 parts chlorpheniramine or a mixture
 of 10-5000 parts propyphenazone and 1-50 parts codeine and a

mixture of 1-50 parts homeopathic preps. of Aconitum, Gelsemium, Eupatorium, Echinacea, Bryonia, or a mixture of 0.01-10 parts homeopathic preps. of white arsenic, Hydrastis, Phytolacca, Medorrhinum, Mezereum, iron phosphate, Influenzium, phosphorus triiodate, Sambucus, and pharmaceutically acceptable excipients.

The preparation may be formed into tablets or capsules.

ACCESSION NUMBER: 2001:189220 CAPLUS Full-text
DOCUMENT NUMBER: 134:212698
TITLE: Analgesic, antipyretic, anti-inflammatory,
flu-preventing medicine
INVENTOR(S): Dobrescu, Dumitru
PATENT ASSIGNEE(S): Rom.
SOURCE: Rom., 3 pp.
CODEN: RUXXA3
DOCUMENT TYPE: Patent
LANGUAGE: Romanian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RO 113712	B3	19981030	RO 1996-353	
19960222 <--				
PRIORITY APPLN. INFO.:			RO 1996-353	
19960222 <--				
IPCI A61K0009-28 [ICM,6]				
IPCR A61K0009-28 [I,C*]; A61K0009-28 [I,A]				
CC 63-6 (Pharmaceuticals)				
IT Drug delivery systems				
(homeopathic; analgesic, antipyretic, anti-inflammatory, flu-preventing formulation)				
IT 50-48-6 50-52-2, Thioridazine 50-78-2, Aspirin 50-81-7, Ascorbic acid, biological studies 58-08-2, Caffeine, biological studies 60-87-7, Promethazine 68-88-2, Hydroxizine 76-57-3, Codeine 103-90-2, Paracetamol 113-92-8, Chlorpheniramine 439-14-5, Diazepam 479-92-5, Propyphenazone 14838-15-4,				
Phenylpropanolamine				
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (analgesic, antipyretic, anti-inflammatory, flu-preventing formulation)				

L16 5 S L5 AND (?HOMEOPATH?)
L17 4 S L16 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)
L18 2 S L17 NOT L15
L19 4 S L6 AND (?HOMEOPATH?)
L20 3 S L19 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)
L21 2 S L20 NOT L15
L22 2 S L21 NOT L18

L22 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN

AB Expts. on animals with transplanted tumors (Lewis lung carcinoma and carcinosarcoma Walker-256) showed that combination treatment

with cyclophosphane and its homeopathically potentiated forms increases antibleastic activity of the preparation

ACCESSION NUMBER: 2003:542972 CAPLUS [Full-text](#)
DOCUMENT NUMBER: 141:64483
TITLE: Potentiated cyclophosphane: Experimental study
of the effect on tumor development and efficiency of
cytostatic therapy
AUTHOR(S): Amosova, E. N.; Zueva, E. P.; Razina, T. G.;
Krylova,
CORPORATE SOURCE: S. G.; Shilova, N. V.; Epstein, O. I.
Pharmacology, Tomsk Research Center, Institute of
Medical Sciences, Tomsk, Russia
SOURCE: Bulletin of Experimental Biology and Medicine
(Translation of Byulleten Eksperimental'noi
Biologii i Meditsiny) (2003), 135-136(Suppl. 1),
107-110
CODEN: BEXBAN; ISSN: 0007-4888
PUBLISHER: Kluwer Academic/Consultants Bureau
DOCUMENT TYPE: Journal
LANGUAGE: English
CC 1-6 (Pharmacology)
ST cyclophosphane potentiated homeopathic bipathic antitumor
cytostatic lunch carcinoma
IT Therapy
(homeopathy; effect of potentiated cyclophosphane on tumor
development and efficiency of cytostatic therapy)
IT 50-18-0, Cyclophosphane
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(effect of potentiated cyclophosphane on tumor development and
efficiency of cytostatic therapy)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE
FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L22 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN
AB Antibodies to cyclophosphamide obtained by homeopathic
potentiation and administered in ultralow doses exhibit no
antibleastic activity and did not modulate the effectiveness of
cyclophosphamide during antitumor therapy of animals with
transplanted tumors (Lewis lung carcinoma and Ehrlich
adenocarcinoma).
ACCESSION NUMBER: 2003:542932 CAPLUS [Full-text](#)
DOCUMENT NUMBER: 140:302022
TITLE: Effect of Potentiated Antibodies to
Cyclophosphamide
of
on the Development of Tumors and Effectiveness
Conditions
Cytostatic Therapy under Experimental
AUTHOR(S): Amosova, E. N.; Zueva, E. P.; Razina, T. G.;

Krylova,
S. G.; Shilova, N. V.; Epstein, O. I.
CORPORATE SOURCE: Tomsk Research Center, Institute of
Pharmacology, Siberian Division of the Russian Academy of
Medical Sciences, Moscow, Russia
SOURCE: Bulletin of Experimental Biology and Medicine
(Translation of Byulleten Eksperimental'noi
Biologii i Meditsiny) (2003), 135-136(Suppl. 1), 54-56
PUBLISHER: CODEN: BEXBAN; ISSN: 0007-4888
DOCUMENT TYPE: Kluwer Academic/Consultants Bureau
LANGUAGE: Journal
English
CC 15-3 (Immunochemistry)
Section cross-reference(s): 1
IT 50-18-0, Cyclophosphamide
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of potentiated antibodies to cyclophosphamide on the
development of tumors and effectiveness of cytostatic therapy
under exptl. conditions)

L23 3 S L7 AND (?HOMEOPATH?)
L24 2 S L23 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)
L25 0 S L24 NOT L15